New treatments for men with castration-resistant prostate cancer: Can we move from small steps to giant leaps?

摘要

In this month's issue of European Urology, Sridhar et al. bring us up to date on the rapidly evolving landscape of approved and emerging treatments for men with castration-resistant prostate cancer (CRPC) [1 ]. After >6 yr with no approvals or positive trials since the demonstration of improved survival with docetaxel, we now have the novel androgen synthesis inhibitor abiraterone acetate, the second-generation anti-androgen enzalutamide, an immunomodulatory cellular therapy (sipuleucel-T, where available), a novel taxane in cabazitaxel, and two bone-targeting agents in radium 223 and denosumab.